Damora completes redomestication to Cayman Islands
Damora Therapeutics completed its redomestication from Delaware to the Cayman Islands on July 16, 2026, following shareholder approval in February. Shares will trade under a new CUSIP starting July 20, 2026, while the business remains unchanged.
*this image is generated using AI for illustrative purposes only.
Damora Therapeutics, Inc. (Damora) has completed its redomestication from the State of Delaware to the Cayman Islands, effective July 16, 2026. The transition does not alter the company’s business, management, obligations, assets, or liabilities. Each outstanding share of the Delaware company’s common stock automatically converted into one ordinary share, with a par value of $0.00001 per share. Preferred stock shares similarly converted on a one-to-one basis for each corresponding series.
The redomestication was approved by Damora’s board of directors and subsequently by stockholders at a Special Meeting held on February 9, 2026. Effective July 20, 2026, the company’s ordinary shares will trade on Nasdaq under a new CUSIP number, G2646Y104. The trading symbol "DMRA" remains unchanged.
Share Conversion Details
| Share Type | Conversion Ratio | New Par Value |
|---|---|---|
| Common Stock | 1:1 | $0.00001 per share |
| Preferred Stock | 1:1 (per series) | Unchanged |
Damora Therapeutics is a biotechnology company focused on developing biologics for hematologic disorders, including essential thrombocythemia and myelofibrosis. The company has multiple programs with best-in-class potential scheduled to enter clinical development in 2026.
How will the redomestication to the Cayman Islands impact Damora's ability to attract future institutional investors?
What specific regulatory advantages does the new corporate structure provide for the upcoming clinical trials in 2026?
Will the change in jurisdiction affect the company's tax obligations or financial reporting requirements?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
